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Abstract. Invasive breast cancer (BC) is infrequent among 
women aged ≤40 years, however, the disease outlook in these 
younger patients is generally worse than among older women. 
The present study aimed to compare socio-demographic, 
clinical and pathological characteristics, and their association 
with long-term survival, between two random cohorts of young 
(≤40 years) and older (50-69 years) Brazilian patients with 
BC. The cohort comprised of 738 randomly selected women 
who were diagnosed with BC at Barretos Cancer Hospital, Pio 
XII Foundation (Barretos, Brazil) between January 1985 and 
December 2002; the patients included young women (n=376) 
and older women (n=362). The current analysis suggested that 
BC in young women is associated with numerous pathological 
features of aggressiveness. Second cancer and bilateral BC 
were independent predictors of a poor outcome in the younger 
group. Furthermore, C-erB-2 was positively correlated with 
poor outcome in the older group, whereas estrogen receptor 
status and TNM stage were associated with disease prognosis 
in both groups. The overall survival rates of the two age 
groups were similar except when analyzed according the treat-
ment period (1997-2002). Although patients aged ≤40 years 
harbored tumors with more aggressive clinicopathological 
characteristics, these characteristics were not independent 
predictors of overall survival. The present study indicates 
that medical advances associated with prevention of breast 
cancer may improve screening programs, which may therefore 
increase early diagnosis and subsequently lower mortality 
rates.
Introduction
Breast cancer (BC) is the most frequent malignancy among 
women worldwide, with an estimated 14 million new cases 
and 8 million mortalities in 2012, which is projected to rise 
by at least 70% by 2030 (1). It is most common in women 
aged >50 years (>75% of all cases), in contrast to those aged 
≤40 years, who represent only 5-25% of all BC cases. Notably, 
BC in these younger women is generally considered to bear a 
more unfavorable disease outcome, with a substantially shorter 
overall survival as compared with older women (2,3).
Indeed, several multivariate analyses have shown that 
young age is an independent predictor of unfavorable disease 
outcome (4), and it has been suggested to be associated with 
a more aggressive tumor biology that potentially reduces the 
survival expectancy (5,6). This increased aggressiveness of BC 
among younger women has been attributed to mutations in the 
BC susceptibility proteins, breast cancer (BRCA)1 and 2 (5,6). 
In addition, BC in younger women is often diagnosed at more 
advanced stages than in older women. In addition, BC tumors 
in younger women are: i) More frequently negative for estrogen 
receptor (ER); ii) show extensive lymphovascular invasion 
(LVI); iii) exhibit increased cell proliferation (assessed by 
the Ki-67 marker); and v) demonstrate overexpression of p53 
oncogene (6).
Molecular profiling has suggested that race and ethnicity 
may be other important factors associated with the develop-
ment of BC, particularly with its poor prognosis among 
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younger women, with those of African American origin 
being at the highest risk of increased mortality (7). All of the 
aforementioned evidence indicates that BC in younger women 
bears a worse disease outcome compared with older women. 
This difference is only partially explained by the fact that 
mammography screening and clinical breast examinations are 
targeted to women aged >40 years (8).
In Brazil, the incidence and mortality rates of BC are 
relatively high (9,10). Compared with North America, where 
the incidence of BC among younger women has plateaued (11), 
Brazil continues to present with relatively high incidence 
rates among women aged 30-39 years (12). Considering the 
increased BC mortality among young women of African 
origin (7), it is of note that Brazil is a country with a relatively 
high population of African descent, increasing the importance 
of assessing the characteristics of BC among young women in 
this country.
To the best of our knowledge, the present study analyzed 
the largest cohort of patients with BC aged ≤40 years (n=376) 
at a single institution to date, by comparing an extensive set of 
clinicopathological characteristics and other variables with a 
similarly sized cohort of BC patients aged 50-69 years (n=362). 
The aim of the present study was to determine whether disease 
outcome in younger women is poorer than that in the older 
women and, if supported, to estimate the significant determi-
nants of this differential outcome in multivariate models.
Patients and methods
Study design. The present retrospective analytical study was 
based on the hospital records of women with invasive BC 
(ICD-10: C50) who were admitted to Barretos Cancer Hospital, 
Pio XII Foundation (Barretos, Brazil) with no previous treat-
ment between January 1985 and December 2002. During this 
17-year period, a total of 4,134 women were examined. Of 
those, 1,735 women were eligible and initially selected into the 
present study, according to the inclusion and exclusion criteria. 
The patients were divided into two groups: A younger group 
(≤40 years of age) and an older group (50-69 years of age). 
The original cohort included 469 patients aged ≤40 years and 
1,266 patients aged 50-69 years. From this original cohort, 
400 women were selected from each group using a random 
sample generator (SPSS software, version 20.0.0.1; IBM 
SPSS, Armonk, NY, USA). Clinical treatment and follow-up 
data were obtained from the patients' medical records. Patients 
without follow-up information for >12 months were contacted 
by telephone to update this information.
Inclusion and exclusion criteria. Patients that had undergone 
cancer treatment prior to admission (1,290 patients), those aged 
41-49 years of age (666 patients) and those aged ≥70 years 
(443 patients) were excluded from the cohort. Finally, 24 women 
were excluded from the ≤40 years age group and 38 women were 
Table I. Demographics of patients with breast cancer stratified by age group.
 ≤40 years (n=376) 50‑69 years (n=362)
 ---------------------------------------------- -----------------------------------------------
Variable n % n % P-value
Period of treatment
  1985-1990   59 15.7 65 18.0 0.078
  1991-1996 108 28.7 78 21.5
  1997-2002 208 55.3 217 59.9
  N/A 1 0.3 2 0.6
Schooling, years
  0-8 210 55.9 279 77.1 <0.001
  9-11 106 28.2 32 8.8
  ≥12 57 15.2 34 9.4
  N/A 3 0.8 17 4.7
Overweight 
  No 284 75.5 219 60.5 <0.001
  Yes 44 11.7 90 24.9
  N/A 48 12.8 53 14.6
Ethnicity
  White 297 79.0 288 79.6 0.360
  Non-white 76 20.2 70 19.3
  N/A 3 0.8 4 1.1
Marital status
  Married 254 67.6 214 59.1 <0.001
  Single/divorced 110 29.3 134 37.0
  N/A 12 3.2 14 3.9
N/A, not available.
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excluded from the 50-69 years age group due to a lack of clinical 
or treatment information, or due to a non-invasive disease.
Sample size estimation. To calculate the sample size, the 
following assumptions were made: 30-40% mortality (13,14), 
±7.5% estimation error, 5% type I error and 90% power. These 
conditions indicated that between 360 and 400 patients in both 
groups would be required for an adequately powered study. 
Accordingly, the final analysis included 376 women aged 
≤40 years and 362 women aged 50‑69 years.
Definitions of BC characteristics. BC was defined as 
multi‑centric or multi‑focal disease. Multi‑centric was defined 
as a disease present in >1 quadrant of the breast, whereas 
multi‑focal disease was defined as a second tumor located at a 
distance of at least 5 cm from the primary tumor. The tumors 
were also classified as synchronous or metachronous. The 
criteria recommended by the National Cancer Institute were 
used to assess comorbidities (15).
Immunohistochemistry (IHC) was routinely performed 
using paraffin sections of the tumors to classify their patterns 
of ER, progesterone receptor (PR) and C-erB-2 oncoprotein 
expression. Tumors that were negative for all of these markers 
were considered ‘triple negative’ for IHC expression. Assess-
ment of positive reactions was performed according to the 
guidelines in common use for ER and PR, and the scoring 
system proposed by Allred et al was used to determine the 
proportion of stained nuclei and the staining intensity (16).
Table II. Main clinical features of patients with breast cancer stratified by age group.
 ≤40 years (n=376) 50‑69 years (n=362)
 --------------------------------------------- ---------------------------------------------
Clinical feature n % n % P-value
Palpable nodules 
  No 19 5.1 20 5.5 0.761
  Yes 356 94.7 338 93.4
  N/A 1 0.3 4 1.1
Multicentric cancer 
  No 358 95.2 344 95.0 0.158
  Yes 11 2.9 5 1.4
  N/A 7 1.9 12 3.3
Multifocal cancer     0.017
  No 346 92.9 341 94.2
  Yes 23 6.1 9 2.5
  N/A 1 0.3 12 3.3
Second cancer  
  No 371 98.7 352 97.2 0.327
  Yes 4 1.1 7 1.9
  N/A 8 2.1 3 0.8
Bilateral breast cancer     0.037
  No 331 88.0 336 92.8
  Yes 37 9.8 21 5.8
  N/A 8 2.1 5 1.4
Familial history 
  No 211 56.1 181 50.0 0.611
  Yes 49 13.0 36 9.9
  Other malignancies 74 19.7 53 14.6
  N/A 42 11.2 92 25.4
Menopause at diagnosis  
  No 363 96.5 38 10.5 <0.001
  Yes 7 1.9 226 62.4
  N/A 6 1.6 98 27.1
Comorbidities      <0.001
  Absent 256 68.1 145 40.1
  1 or 2 diseases 114 30.8 175 48.3
  N/A 6 1.6 42 11.6
N/A, not available.
 
VAZQUEZ et al:  BREAST CANCER IN YOUNG WOMEN IN BRAZIL4914
Table III. Histological features of patients with breast cancer stratified by age group.
 ≤40 years (n=376) 50‑69 years (n=362)
 ------------------------------------------ -------------------------------------------
Histological feature n % n % P-value
Histological diagnosis 
  Ductal carcinoma  301 80.1 289 79.8 0.867
  Lobular carcinoma  59 15.7 54 14.9
  Miscellaneous 15 4.0 17 4.7
  N/A 1 0.3 2 0.6
Tumor size (mastectomy), cm 
  ≤2 54 14.4 74 20.4 0.185
  >2 187 49.7 195 53.9
  N/A 135 35.9 93 25.7
Ta 
  TI/TII 196 52.1 210 58.0 0.354
  TIII/TIV 84 22.3 106 29.3
  N/A 94 25.0 46 12.7
Na 
  Positive 147 39.1 156 43.1 0.183
  Negative 197 52.4 170 47.0
  N/A 32 8.5 36 9.9
Ma 
  No 311 82.7 311 85.9 0.740
  Yes 38 10.1 35 9.7
  N/A 27 7.2 16 4.4
Differentiation degree
  I/II 190 50.5 201 55.5 0.035
  III 87 23.1 60 16.6 
  N/A 99 26.3 101 27.9
Perineural invasion     
  No 241 64.1 84 23.2
  Yes 18 4.8 13 3.6 0.055
  N/A 117 31.1 276 76.8
Blood vessel invasion     
  No 248 66.0 79 21.8
  Yes 4 1.1 7 1.9 0.007
  N/A 124 33.0 276 76.2
Lymphovascular invasion     
  No 189 50.3 53 14.6 <0.001
  Yes 80 21.3 81 22.4  
  N/A 107 28.5 228 63.0
Lymph node invasion
  N1 (1-3) 78 20.7 67 18.5 0.535
  N2 (4-9) 55 14.6 49 13.5
  N3 (≥10)  42 11.2 35 9.7
  N/A 201 53.5 211 58.3
Estrogen receptor     
  Negative 89 23.7 67 18.5 0.014
  Positive 126 33.5 155 42.8
  N/A 161 42.8 140 38.7
Progesterone receptor
  Negative 90 23.9 85 23.5 0.468
  Positive 124 33.0 135 37.3
  N/A 162 43.1 142 39.2
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Tumor staging was based on the criteria proposed by the 
International Union Against Cancer and the American Joint 
Committee on Cancer (17), and the TNM staging system was 
used to evaluate the BC in three aspects: Tumor size and exten-
sion (T), regional lymph node involvement (N), and the presence 
of distant metastasis (M). Following the determination of the T, 
N and M classifications, stage 0, I, II, III or IV was assigned.
Statistical analysis. Statistical analyses were run using SPSS 
software for Windows (version 20.0.0.1; IBM SPSS). Frequency 
tables used for univariate analysis of overall survival (OS; the 
time from diagnosis until mortality or date last seen alive) were 
based on the Kaplan-Meier method, where stratum-specific 
outcomes were compared using log-rank (Mantel-Cox) 
statistics. To adjust for covariates, a Cox proportional hazards 
regression model was used, and covariates (as listed separately) 
were entered in a stepwise backwards manner using the default 
values of entry (P=0.05) and removal (P=0.10). The variables 
that were significant in the univariate analysis were included in 
the multivariate model. All of the statistical tests were two-sided 
and P<0.05 indicated a statistically significant difference.
Ethics. The present study was approved by the Research Ethics 
Committee of Barretos Cancer Hospital, Pio XII Foundation. 
Results
The demographic characteristics of the patients in the two 
series are presented in Table I. The main clinical features are 
Table III. Continued.
 ≤40 years (n=376) 50‑69 years (n=362)
 ----------------------------------------- -----------------------------------------
Histological feature n % n % P-value
C-erB-2 oncoprotein
  Negative 117 31.3 125 34.5 0.032
  Positive 58 15.4 53 14.6
  N/A 201 53.5 184 50.8
Triple negative      
  No 136 36.2 155 42.8 0.027
  Yes 38 10.1 23 6.4 
  N/A 202 53.7 184 50.8
Type of breast surgery
  Without surgery 37 9.8 24 6.6 0.078
  Lumpectomy 26 6.9 36 9.9
  Quadrantectomy 87 23.1 66 18.2
  Mastectomy 224 59.6 234 65.6 
  N/A 2 0.5 2 0.6
Axillary surgery
  No 58 15.4 62 17.1 0.219
  Yes 316 84.0 298 82.3
  N/A 2 0.5 2 0.6
Number of lymph nodes dissected
  1-10 61 16.2 53 14.6 0.762
  11-15 76 20.2 77 21.3
  16-20 77 20.5 86 23.8
  ≥2 151 40.2 144 39.8
  N/A 11 2.9 2 0.6
aTNM, tumor-node-metastasis staging. N/A, not available.
 
Figure 1. Overall survival rates of younger (n=376) and older (n=362) women 
with breast cancer.
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shown in Table II. The histopathological features and treatment 
characteristics are shown in Tables III and IV, respectively.
The two groups displayed significant differences in various 
characteristics. The older group showed a higher proportion 
of women with low educational level (up to 8 years of school) 
as compared with the younger group (77.1 vs. 55.9%, respec-
tively; P<0.001) (Table I). 
Table II shows that the groups had no differences in 
the presence of nodules or multicentric cancer at the first 
examination. The younger group had a higher proportion of 
multi-focal cancer and bilateral cancer as compared with the 
older group (6.1 vs. 2.5%, P=0.017 and 9.8 vs. 5.8%, P=0.037, 
respectively). Comorbidity was less frequent in the younger 
group than in the older group; one or two comorbidities were 
found in 30.3 vs. 48.3% of patients (P<0.001), respectively 
(Table II).
As indicated in Table III, no significant differences were 
identified between the groups in terms of histological types of 
the cancer or disease staging. The tumors in the younger group 
showed a greater frequency of a low degree of differentiation 
(23.1 vs. 16.6%; P=0.035), reduced blood vessel invasion 
(1.1 vs. 1.9%; P=0.003), reduced LVI (21.3 vs. 22.4%; P<0.001) 
and reduced perineural invasion (4.8 vs. 3.6%; P=0.055) as 
compared with the lesions in the older group (Table III). 
The proportion of tumors that were positive for ER 
expression was significantly lower in the younger group than 
in the older group (33.5 vs. 42.8%; P=0.014). The two groups 
had similar negative rates of PR and C-erB-2 expression 
(Table III). Tumors classified as triple negative were more 
frequent among the younger women (10.1 vs. 6.4%; P=0.027) 
(Table III).
The two groups were similar in terms of the number of 
dissected lymph nodes. Although the younger group under-
went radical mastectomy less frequently than the older group, 
the difference was not statistically significant (59.6 vs. 64.6%, 
respectively; P=0.078) (Table III). There was a higher propor-
tion of breast reconstruction in the younger group as compared 
with the older group (20.7 vs. 3.9%; P<0.001) (Table IV). 
Furthermore, the groups had undergone similar neo-adjuvant 
treatments Table IV); adjuvant hormone therapy was used 
less frequently in the younger than in the older group, but this 
difference was only of borderline significance (27.7 vs. 36.2%; 
P=0.056) (Table IV).
The duration of follow-up ranged between 0 and 22.6 years, 
with a mean of 6.1 years and 8.5 months when mortality was 
excluded. The follow-up data were similar in the two groups 
(P=0.816). After 5 and 10 years, 4.9 and 10.5% of the patients, 
respectively, were lost to follow-up (data not shown). The 
Table IV. Treatment of patients with breast cancer, stratified by age group.
 ≤40 years (n=376) 50‑69 years (n=362)
 -------------------------------------------- --------------------------------------------
Treatment n % n % P-value
Breast reconstruction
  Without 295 78.5 346 95.6 <0.001
  Immediate 35 9.3 6 1.7
  Late 43 11.4 8 2.2
  N/A 3 0.8 2 0.6
Neoadjuvant chemotherapy
  No 312 83.0 286 79.0 0.254
  Yes 62 16.5 71 19.6
  N/A 2 0.5 5 1.4
Chemotherapy
  No 52 13.8 70 19.3 0.053
  Yes (adjuvant) 201 53.5 196 54.1
  Yes (palliative) 120 31.9 92 25.4
  N/A 3 0.8 4 1.1
Hormone therapy
  No 206 54.8 176 48.6
  Yes (adjuvant) 104 27.7 131 36.2 0.056
  Yes (palliative) 59 15.7 51 14.1
  N/A 7 1.9 4 1.1
Radiotherapy 
  No 69 18.4 72 19.9 0.592
  Yes 302 80.3 284 78.5
  N/A 5 1.3 6 1.7
N/A, not available.
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OS rates were not significantly different between the groups 
(P=0.421) (Fig. 1).
Univariate analysis showed that the following characteristics 
were significantly associated with prognosis in the younger 
group: Second cancer (P=0.004), bilateral BC (P=0.100), familial 
history (P=0.086), menopause at diagnosis (P=0.026), associ-
ated diseases (P=0.077), tumor size (mastectomy) (P=0.075), T, 
N and M stage (P<0.001), degree of differentiation (P=0.127), 
perineural invasion (P=0.056), LVI (P=0.004), lymph node inva-
sion (P<0.001), ER status (P=0.002), PR status (P=0.043), type 
of breast surgery (P<0.001), axillary surgery (P<0.001), number 
of lymph nodes dissected (P<0.001), breast reconstruction 
(P<0.001), neoadjuvant chemotherapy (P<0.028), chemotherapy 
(P<0.001) and hormone therapy (P<0.001) (Tables V-VIII).
In the older group, the following variables were significantly 
associated with prognosis: Period of treatment (P=0.002), 
ethnicity (P=0.129), marital status (P=0.170), palpable nodules 
(P=0.062), tumor size (mastectomy) (P=0.042), T, N and M stage 
(P<0.001), degree of differentiation (P<0.001), peri-neural inva-
sion (P=0.095), blood vessel invasion(P<0.001), LVI (P=0.003), 
lymph node invasion (P<0.001), ER status (P=0.001), PR status 
(P=0.015), C-erB-2 expression (P=0.006), type of breast surgery 
(P<0.001), axillary surgery (P<0.001), number of lymph nodes 
dissected (P=0.005), neo-adjuvant chemotherapy (P=0.010), 
chemotherapy (P<0.001), hormone therapy (P<0.001), and 
radiotherapy (P=0.016). None of the other variables were statis-
tically significant predictors of survival (Tables V‑VIII).
When stratified by clinical stage, no significant differences 
in the stage‑specific survival rates between the two age groups 
were found (P=0.421) (Fig. 1). However, when the groups were 
stratified by the period of treatment, significant differences in 
survival rates were observed between the two groups during the 
treatment period between 1997 and 2002 (young vs. old group, 
40.7 vs. 60.0% survival, P=0.028) (Fig. 2). 
In the multivariate analysis, second cancer [hazard ratio 
(HR), 2.20; 95% confidence interval (CI), 1.500-29.044; 
P=0.013] and bilateral BC (HR, 6.60; 95% CI, 1.228-3.930; 
P=0.008) were independent predictors of a poor outcome, with 
an increased risk of mortality in the younger group. C-erB-2 
(HR, 1.97; 95%; CI, 1.003-3.869; P=0.049) was a positive 
predictor of a poor outcome in the older group, showing an 
increased risk of mortality. The ER status and TNM stage were 
significantly associated with disease prognosis in both groups 
(Tables IX and X).
Discussion
The results described herein reveal important differences 
between the younger and older patients with BC. This is an 
almost unanimously accepted fact among BC investigators. 
Table V. DSS according to the demographics of patients with breast cancer, stratified by age group.
 ≤40 years (n=376) 50‑69 years (n=362)
 ------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------
Variable n 10-year DSS, % P-value n 10-year DSS, % P-value
Period of treatment
  1985-1990 59 46.1 0.656 65 33.3 0.002
  1991-1996 108 46.4  78 42.0 
  1997-2002 208 40.7  217 60.0 
  N/A 1   2  
Schooling, years 
  0-8 210 42.5 0.751 279 50.0 0.551
  9-11 106 48.5  32 44.6 
  ≥12 57 47.5  34 38.5 
  N/A 3   17  
Overweight 
  No 284 48.1 0.624 219 47.5 0.978
  Yes 44 34.1  90 44.9 
  N/A 48   53  
Ethnicity
  White 297 46.0 0.534 288 50.1 0.129
  Non-white 76 42.7  70 41.0 
  N/A 3   4  
Marital status
  Married 254 44.2 0.538 214 52.2 0.170
  Single/divorced 110 49.5  134 42.6   
  N/A 12   14  
DSS, disease‑specific survival; N/A, not available.
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Notably, however, the present study was unable to confirm the 
most controversial of these issues, the suggested worse survival 
rate of young patients with BC, and failed to identify any 
difference in disease outcome between the two study groups. 
This finding is of major importance, asthe OS (Kaplan-Meier) 
did not reveal significant differences between the two groups, 
despite several parameters indicating that a more aggressive 
tumor biology is confined to the younger patients. Only when 
calculated for the treatment period 1997-2002 were the OS 
rates significantly worse among young women. We propose 
that there are several explanations for this finding, with insights 
discussed herein.
Whether there are clinicopathological differences in BC 
between younger and older women remains a controver-
sial issue. Typically, the young BC age group ranges from 
35 (13,18,19) to 40 (2,14,20,21), however, there is no clear 
consensus supporting these strict age limits for young and old. 
However, BC is more frequent in women aged >50 years old. 
In a population-derived cohort from Brazil, the prevalence of 
BC was found to be 14% (12), 4.5% of these patients were aged 
≤35 years (3) and 26.4% were aged ≤40 years (2).
Thus, in the present study, a 40-year cut-off was used to 
stratify the women as younger or older. This criterion was 
partially supported by epidemiological data demonstrating 
Table VI. DSS according to the clinical characteristics of patients with breast cancer, stratified by age group.
 ≤40 years (n=376) 50‑69 years (n=362)
 ---------------------------------------------------------------------------------- ---------------------------------------------------------------------------------
Clinical characteristic n 10-year DSS, % P-value n 10-year DSS, % P-value
Palpable nodules 
  No 19 66.7 0.216 20 78.9 0.062
  Yes 356 43.9  338 46.3
  N/A 1   4 
Multicentric cancer
  No 358 46.8 0.413 344 48.9 0.428
  Yes 11 26.0  5 50.0
  N/A 7   12 
Multifocal cancer
  No 346 6.2 0.799 341 48.4 0.634
  Yes 23 43.3  9 66.7
  N/A 1   12 
Second cancer 
  No 371 45.7 0.004 352 47.8 0.545
  Yes 4 25.0  7 71.4
  N/A 8   3 
Bilateral breast cancer
  No 331 48.5 0.100 336 48.8 0.575
  Yes 37 30.1  21 46.2
  N/A 8   5 
Familial history
  No 211 38.8 0.086 181 54.9 0.495
  Yes 49 56.7  36 61.7
  Other malignancies 74 46.6  53 36.0
  N/A 42   92 
Menopause at diagnosis
  No 363 45.4 0.026 38 28.5 0.283
  Yes 7 19.0  226 45.4
  N/A 6   98 
Associated diseases 
  Absent 256 40.2 0.077 145 53.1 0.925
  1 or 2 diseases 114 55.7  175 42.8
  ≥3 diseases 5 40.0  40 46.3
  N/A 1   2 
DSS, disease‑specific survival; N/A, not available.
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Table VII. OS according to the histological characteristics of patients with breast cancer, stratified by age group.
 ≤40 years (n=376) 50‑69 years (n=362)
 -------------------------------------------------------------------------------- ---------------------------------------------------------------------------------
Histological characteristic n 10-year OS, % P-value n 10-year OS, % P-value
Histological diagnosis 
  Ductal carcinoma  301 47.8 0.212 289 46.4 0.429
  Lobular carcinoma  59 32.4  54 58.2 
  Miscellaneous 15 53.0  17 58.5 
  N/A 1   2
Tumor size (mastectomy) 
  ≤2 cm 54 65.0 0.075 74 57.1 0.042
  >2 cm 187 49.9  195 52.1 
  N/A 135   93
Stage 
  I 38 90.9 <0.001 37 66.8 <0.001
  II 136 66.2  135 67.6 
  III 101 20.4  122 28.3 
  IV 44 0.049  39 - 
  N/A 57   29
Ta 
  TI/TII 196 56.8 <0.001 210 62.8 <0.001
  TIII/TIV 84 32.6  106 26.5 
  N/A 94   46
Na 
  Negative 147 70.3 <0.001 156 70.1 <0.001
  Positive 197 32.3  170 33.3 
  N/A 32   36
Ma
  No 311 50.1 <0.001 311 50.4 <0.001
  Yes 38 -  34 - 
  N/A 27   17
Differentiation degree 
  I/II 190 45.1 0.127 201 58.0 <0.001
  III 87 46.9  60 23.5 
  N/A 99   101
Perineural invasion 
  No 241 47.3 0.056 84 65.0 0.095
  Yes 18 -  13 - 
  N/A 117   278
Blood vessel invasion 
  No 248 45.9 0.431 79 68.7 <0.001
  Yes 4 -  7 - 
  N/A 124   276
Lymphovascular invasion 
  No 189 53.8 0.004 53 76.8 0.003
  Yes 80 30.5  81 29.4 
  N/A 107   228
Lymph node invasion 
  N1 (1 to 3) 78 53.7 <0.001 67 52.2 <0.001
  N2 (4 to 9) 55 34.8  49 13.8 
  N3 (≥10)  42 14.4  35 ‑ 
  N/A 201   211
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different tumor biology in different age groups (14,22). 
It is also important to emphasize that in Europe, regular 
mammography screening is a standard practice for women 
aged 50-69 years. This group is considered to be a biologically 
distinct group at high risk of developing BC with particular 
radiological characteristics (23). For this reason, women aged 
50-69 years old were selected for comparison in the present 
study. As BC studies have different definitions regarding age 
groups, it is challenging to provide a reasonable comparison 
between different studies.
A number of reports also disagree regarding the importance 
of including different types of BC, for example, carcinoma 
in situ (CIS) (13,21) or metastatic disease (2,24). Other studies 
disagree regarding the pertinence of including patients with 
clinical stage I and II (25,26) or clinical stages I-III (2,20,24) 
cancer. The present study included TNM stage, and excluded 
cases of CIS due to their different histological features (27) 
and relatively favorable disease outcome.
The present study is based on robust parameters that were 
selected to reflect the true significance of the behavior of BC in 
young women. To the best of our knowledge, the current study 
includes the largest cohort of patients with BC aged ≤40 years 
(n=376) reported from a single institution to date. Worldwide, 
few institutions have studied larger samples (24,28) and the 
majority of large studies have been based on cancer regis-
tries (7,14,21).
Table VII. Continued.
 ≤40 years (n=376) 50‑69 years (n=362)
 ---------------------------------------------------------------------------- ---------------------------------------------------------------------------
Histological characteristic n 10-year OS, % P-value n 10-year OS, % P-value
Estrogen receptor 
  Negative 89 16.7 0.002 67 31.2 0.001
  Positive 126 47.8  155 60.4 
  N/A 161   140
Progesterone receptor 
  Negative 90 16.2 0.043 85 46.3 0.015
  Positive 124 49.0  135 56.4 
  N/A 162   142   
C-erB-2 oncoprotein 
  Negative 117 33.0 0.332 125 66.5 0.006
  Positive 58 18.9  53 50 
  N/A 201   184
Triple negative  
  No 136 25.2 0.711 155 69 0.236
  Yes 38 26.0  23 68.8
  N/A 202   184
Type of breast surgery 
  Without surgery 37 - <0.001 24 - <0.001
  Lumpectomy 26 0  36 35.3 
  Quadrantectomy 87 61.6  66 75.7 <0.001
  Mastectomy 224 47.9  234 46.6 
  N/A 2   2
Axillary surgery 
  No 58 0 <0.001 62 24.1 <0.001
  Yes 316 51.8  298 52.3 
  N/A 2   2
Number of lymph nodes dissected 
  1 to 10 61 61.1 <0.001 53 53.3 0.005
  11 to 15 76 43.9  77 42 
  16 to 20 77 63.8  86 58.7 
  21 and over 151 25.1  144 40.9
  N/A 11   2
aTNM, tumor-node-metastasis staging; N/A, not available.
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Table IX. Multivariate survival analysis of patients aged ≤40 years (n=178).
Variable n Hazard ratio 95% confidence interval P‑value
Bilateral breast cancer 
  No 158 - - -
  Yes 20 2.20 1.228-3.930 0.008
Second cancer 
  No 176 - - -
  Yes 2 6.60 1.500-29.044 0.013
Estrogen receptor 
  Positive 106 - - -
  Negative 72 2.29 1.389-3.777 0.001
T 
  I/II 133 - - -
  III/IV 45 2.14 1.258-3.640 0.005
N 
  No 80 - - -
  Yes 98 2.66 1.531-4.621 0.001
M 
  No 173 - - -
  Yes 5 5.92 2.172-16.151 0.001
 
Table VIII. DSS according to the treatment of patients with breast cancer, stratified by age group.
 ≤40 years (n=376) 50‑69 years (n=362)
 ------------------------------------------------------------------------------- --------------------------------------------------------------------------------
Treatment n 10-year DSS, % P-value n 10-year DSS, % P-value
Breast reconstruction 
  Without 295 41.0 <0.001 346 47.7 0.263
  Immediate 35 43.3  6 -
  Late 43 75.7  8 83.3
  N/A 3   2
Neoadjuvant chemotherapy 
  No 312 48.4 0.028 286 51.0 0.010
  Yes 62 28.2  71 37.3
  N/A 2   5
Chemotherapy 
  No 52 65.5 <0.001 70 49.6 <0.001
  Yes-adjuvant 201 60.9  196 62.5
  Yes-palliative 120 14.0  92 19.0
  N/A 3   4
Hormone therapy 
  No 206 51.8 0.001 176 52.5 <0.001
  Yes-adjuvant 104 50.3  131 53.2
  Yes-palliative 59 10.8  51 11.2
  N/A 7   4
Radiotherapy 
  No 69 50.5 0.935 72 36.7 0.016
  Yes 302 43.2  284 52.9
  N/A 5   6
DSS, disease‑specific survival; N/A, not available.
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The present study included a large number of patients 
with invasive BC presenting at advanced clinical stages. 
These features are not unusual and are inherent to the existing 
healthcare system in Brazil. Brazilian women have limited 
access to clinics that provide mammography examinations 
and organized population-based screening programs do not 
exist; consequently, the majority of the BC cases in Brazil are 
detected at advanced stages. This is in contrast to the situa-
tion in developed countries, where regular mammography 
screening enables the detection of the majority of cases of BC 
at an early stage (14,19,21). Indeed, prior to 2002, there was no 
formal recommendation from the Brazilian Health Authori-
ties to provide mammography examinations in asymptomatic 
women. Therefore, as the presence of palpable and/or ulcer-
ated lesions were a requirement for medical care, a substantial 
proportion of women exhibited these signs at their first exami-
nation. These characteristics are an inherent bias of the present 
study design resulting in a cohort enriched by BC patients with 
aggressive tumors at baseline. However, the overall relative 
survival rate of the older women (50-69 years old) improved 
between 1997 and 2002, attributable to improvements in treat-
ment, such as chemotherapy and hormone therapy (29).
Mammography is undoubtedly an important diagnostic tool 
for non-palpable lesions, despite sensitivity limitations among 
women aged ≤40 years. It is speculated that regular programs 
for BC prevention could minimize the number of cases of 
advanced stage disease in Brazil (30). Hereditary BC associ-
ated with BRCA1/2 mutations have a prevalence of ~2.3% (31) 
in Brazil. Furthermore, studies of Latin American women 
have demonstrated that a family history of BC is less prevalent 
in Latin America than in the North American population (32). 
In the present study, mutations were not investigated, however, 
the familial history of BC was similar between the two study 
groups. However, the presence of second cancer was similar in 
the younger and older groups; this is consistent with the results 
of a previous study, where it was attributed to longer exposures 
to pathogenic factors (33).
The prevalence of bilateral disease was higher in the 
younger age group and is one of the indicators of more 
aggressive tumors, for example tumors with T stage II/III, 
grade III differentiation, negative ER/PR status and positive 
lymph node invasion are more aggressive (33). Conversely, the 
older women more frequently presented with other diseases 
associated with their BC, which can have an adverse influence 
on clinical outcome and contribute to a poor prognosis (34). 
However, the present results identified indicators of worse 
prognosis to be more common among the younger women.
Figure 2. Overall survival rates of younger (n=208) and older (n=217) women 
with breast cancer in the treatment period between 1997 and 2002.
Table X. Multivariate survival analysis of patients aged 50-69 years (n=151).
Variable n Hazard ratio 95% confidence interval P‑value
Estrogen receptor 
  Positive 44 - - -
  Negative 107 2.34 1.175-4.663 0.016
C-erB-2 oncoprotein
  Negative 108 - - -
  Positive 43 1.97 1.003-3.869 0.049
Ta 
  I/II 110 - - -
  III/IV 41 2.12 1.073-4.180 0.030
Na
  No 71 - - -
  Yes 80 2.93 1.394-6.149 0.005
Ma 
  No 150 - - -
  Yes 1 9.99 1.049-95.105 0.045
aTNM, tumor-node-metastasis staging.
ONCOLOGY LETTERS  12:  4911-4924,  2016 4923
Accordingly, younger women presented with a higher 
proportion of tumors with grade III differentiation (poorly 
differentiated), as reported in a previous study (33). Similarly, 
the present study observed significant differences between the 
two groups in terms of perivascular blood vessel invasion and 
LVI, with older women showing higher proportions of both 
types of invasion. Notably, this result conflicts with the previ-
ously reported data (35,36).
The present study also observed that a higher proportion 
of older women were positive for ER compared with younger 
women. This finding is consistent with the results of a previous 
study, in which advanced age was correlated with positive ER 
status and vice versa (36). This observation also agrees with 
the disease outcome data of the current cohort, as a negative 
ER status is typically associated with a more unfavorable 
prognosis. By contrast, PR expression did not significantly 
differ between the two age groups, in agreement with a 
previous report (26). Conversely, a previous study observed 
that a negative PR status occurs more frequently in the BC of 
younger women (35). However, the prognostic value of PR was 
visible only as a part of an algorithm, but not on its own (37). 
The present findings also revealed that triple negative BC, 
which are considered to predict a poor prognosis, were more 
common in younger women, as previously reported (13).
As anticipated, more important differences in factors that 
usually influence the efficacy of treatment were observed 
between the two groups, including tumor stage at the time of 
diagnosis, tumor characteristics and comorbidities. Of note, 
the present study included patients with follow-up times of 
up to 22 years (mean, 6.75 years). This is another important 
feature of the present study, as only a small number of studies 
have reported long-term follow-up data of 10 (20,25,36,38) 
or 15 years (2,14,24,28). In addition, BC treatment strategies 
have undergone rapid developments in the past two decades, 
and this development may have contributed to the prognostic 
differences between the two groups included in the current 
study. In the younger group, fewer patients received adjuvant 
hormone therapy and more women received palliative chemo-
therapy when compared with the older group. This is a clear 
limitation inherent to all retrospective studies where active 
intervention is no longer possible. However, the current obser-
vations clearly support proposals to also initiate monitoring 
programs for long-term BC patients.
Finally, the present results did not show significant differ-
ences in survival rates between the two study groups (Fig. 1). 
By contrast, a previous study conducted in central Brazil 
demonstrated a significant difference in survival rates between 
patients aged ≤40 years and those aged 40‑50 years (P=0.0002) 
or those aged >50 years (P=0.03). However, this study excluded 
clinical stage IV disease and included far fewer patients than 
the present study (20). A previous study reported that BC 
mortality remains high among young patients, with an OS of 
~60% over 5 years, compared with 85% among women aged 
>50 years (20). The equal survival rates between young and 
old women observed in the present study have been reported in 
previous studies (38,39), however, in general, the results have 
been highly variable among the published literature (40-43).
In conclusion, BC among young women is generally 
considered to be more aggressive and associated with a worse 
prognosis compared with BC in older women, whereas the 
prognostic value of age itself remains more controversial. The 
results of the present study suggest that BC in young women 
is associated with numerous pathological features of aggres-
siveness, including tumor grade, hormone receptor status and 
degree of differentiation, having been implicated as independent 
determinants of BC prognosis. However, the OS rates of the two 
age groups proved to be very similar, except when the data were 
stratified by the treatment period. For women treated during 
1997-2002, the 10-year survival rate of the older women was 
~60% compared with 40.7% in the younger cohort. The current 
study concludes that this increase in 10-year survival is due 
largely to improvements in treatment, increased early diagnosis 
and certain tumor characteristics, with the patient's age itself not 
being an independent prognostic factor. The present study indi-
cates that medical advances associated with prevention of breast 
cancer may improve screening programs, which may therefore 
increase early diagnosis and subsequently lower mortality rates.
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